Allurion shares surge 12.5% intraday on strong Q4 revenue growth and improved operating expenses.

Allurion surged 12.5% intraday following the announcement of preliminary Q4 and full-year 2025 results, highlighting 22%-37% quarter-over-quarter revenue growth and significant improvements in operating expenses and losses. The company attributed the performance to its strategic pivot in 2025 and anticipation of potential FDA approval for its Allurion Smart Capsule, positioning 2026 as a pivotal year. CEO Dr. Shantanu Gaur emphasized the new commercial strategy’s success in driving revenue and reducing losses, reinforcing optimism about the product pipeline and operational efficiency. The bullish news aligned with the stock’s upward movement, reflecting investor confidence in the company’s strategic direction and regulatory milestones.